Pre-exposure prophylaxis (PrEP) employs antiretroviral agents in HIV-negative individuals to avert viral acquisition. Initial efficacy trials of daily oral regimens combining emtricitabine and ...

Pre-exposure prophylaxis (PrEP) has emerged as a transformative biomedical intervention to prevent HIV infection among people at substantial risk. Its adoption reflects a complex interplay of clinical ...

In a far-reaching effort to understand the factors contributing to HIV transmission among sexual and gender minority (SGM) individuals and improve HIV prevention strategies, a team of scientists at ...

For several years, pre-exposure prophylaxis against HIV (PrEP) has been a major success in preventing new cases. However, individuals on PrEP typically engage in riskier sexual behavior and thus are ...

Lenacapavir (LEN) has arrived in South Africa, and this injectable form of pre-exposure prophylaxis (PrEP) marks a major ...

Background Understanding the ‘real-world’ challenges of delivery of pre-exposure prophylaxis (PrEP) among men who have sex ...

The EUA was supported by primary data from the phase 3 PROVENT trial. The Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for Evusheld (tixagevimab co-packaged with ...

Cuts from the U.S. and others have hit hard, with the number of people receiving PrEP dropping by 38% from 2024 to 2025, ...

HIV-1 infection remains a major public health problem, with an estimated 38.4 million people living with HIV and 1.5 million new HIV infections reported worldwide in 2021. The risk of HIV infection ...

What is Pre-Exposure Prophylaxis (PrEP)? Pre-Exposure Prophylaxis (PrEP) is an HIV prevention strategy that enables HIV-negative people to stay HIV-negative by taking anti-HIV drugs (also called ...

Witkoppen patients are asking if long acting HIV prevention could mean more privacy, less stigma, and one less thing to ...